Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection
Source abstract
Abstract
Clinical follow-up aided by changes in the expression of circulating microRNAs (miRs) may improve prognostication of pancreatic ductal adenocarcinoma (PDAC) patients. Changes in 179 circulating miRs due to cancer progression in the transgenic KrasG12D/+; Trp53R172H/+; P48-Cre (KPC) animal model of PDAC were analyzed for serum miRs that are altered in metastatic disease. In addition, expression levels of 250 miRs were profiled before and after pancreaticoduodenectomy in the serum of two patients with resectable PDAC with different progression free survival (PFS) and analyzed for changes indicative of PDAC recurrence after resection. Three miRs that were upregulated ≥3-fold in progressive PDAC in both mice and patients were selected for validation in 26 additional PDAC patients before and after resection. We found that high serum miR-125b-5p and miR-99a-5p levels after resection are significantly associated with shorter PFS (HR 1.34 and HR 1.73 respectively). In situ hybridization for miR detection in the paired resected human PDAC tissues showed that miR-125b-5p and miR-99a-5p are highly expressed in inflammatory cells in the tumor stroma, located in clusters of CD79A expressing cells of the B-lymphocyte lineage. In conclusion, we found that circulating miR-125b-5p and miR-99a-5p are potential immune-cell related prognostic biomarkers in PDAC patients after surgery.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · Extracellular vesicles in disease · Circular RNAs in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
Department of Surgery, Erasmus MC, University Medical Center Rotterdam, 3015GD Rotterdam, The Netherlands
Department of Pathology, Erasmus MC, University Medical Center Rotterdam, 3015GD Rotterdam, The Netherlands
References (61)
Show source-provided references
1. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states10.1158/0008-5472.CAN-14-0155 ↗
2. Has survival improved following resection for pancreatic adenocarcinoma?10.1016/j.amjsurg.2017.05.007 ↗
3. Nationwide prospective audit of pancreatic surgery: Design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit10.1016/j.hpb.2017.06.010 ↗
4. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors10.1097/00000658-199603000-00007 ↗
5. Impact of expanding indications on surgical and oncological outcome in 1434 consecutive pancreatoduodenectomies10.1016/j.hpb.2018.10.020 ↗
6. Management of patients with pancreatic adenocarcinoma: National trends in patient selection, operative management, and use of adjuvant therapy10.1016/j.jamcollsurg.2011.09.022 ↗
7. MiRBase: MicroRNA sequences, targets and gene nomenclature10.1093/nar/gkj112 ↗
8. The widespread regulation of microRNA biogenesis, function and decay10.1038/nrg2843 ↗
9. Regulation of immune responses and tolerance: The microRNA perspective10.1111/imr.12060 ↗
10. MicroRNA in the immune system, microRNA as an immune system10.1111/j.1365-2567.2009.03092.x ↗
11. MicroRNA biogenesis pathways in cancer10.1038/nrc3932 ↗
12. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells10.1038/ncb1596 ↗
13. Secretory mechanisms and intercellular transfer of microRNAs in living cells10.1074/jbc.M110.107821 ↗
14. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis10.1016/j.gene.2018.06.037 ↗
15. Plasma miRNAs effectively distinguish patients with pancreatic cancer from controls: A multicenter study10.1097/SLA.0000000000001345 ↗
16. Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study10.18632/oncotarget.9491 ↗
17. Plasma microRNA profiles: Identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer10.1038/bjc.2015.366 ↗
18. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer10.4251/wjgo.v6.i1.22 ↗
19. Kawaguchi, T., Komatsu, S., Ichikawa, D., Tsujiura, M., Takeshita, H., Hirajima, S., Miyamae, M., Okajima, W., Ohashi, T., and Imamura, T. (2016). Circulating microRNAs: A next-generation clinical biomarker for digestive system cancers. Int. J. Mol. Sci., 17.10.3390/ijms17091459 ↗
20. Clinical relevance of circulating cell-free microRNAs in cancer10.1038/nrclinonc.2014.5 ↗
21. Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib10.1186/s40169-017-0169-y ↗
22. Circulating biomarkers to monitor cancer progression and treatment10.1016/j.csbj.2016.05.004 ↗
23. Trp53r172h and krasg12d cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice10.1016/j.ccr.2005.04.023 ↗
24. High-performance quantification of mature microRNAs by real-time RT-PCR using deoxyuridine-incorporated oligonucleotides and hemi-nested primers10.1261/rna.2001610 ↗
25. A novel and universal method for microRNA RT-qPCR data normalization10.1186/gb-2009-10-6-r64 ↗
26. Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets10.1158/0008-5472.CAN-04-0496 ↗
27. Current strategies for detection and treatment of recurrence of pancreatic ductal adenocarcinoma after resection: A nationwide survey10.1097/MPA.0000000000000899 ↗
28. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9
29. Van der Sijde, F., Vietsch, E.E., Mustafa, D.A.M., Besselink, M.G., Groot Koerkamp, B., and van Eijck, C.H.J. (2019). Circulating biomarkers for prediction of objective response to chemotherapy in pancreatic cancer patients. Cancers, 11.10.3390/cancers11010093 ↗
30. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer10.1038/bjc.1986.35 ↗
31. Clinical utilization of serum- or plasma-based miRNAs as early detection biomarkers for pancreatic cancer: A meta-analysis up to now10.1097/MD.0000000000012132 ↗
32. Circulating microRNA-99 family as liquid biopsy marker in pancreatic adenocarcinoma10.1007/s00432-018-2749-7 ↗
33. The validity of circulating microRNAs in oncology: Five years of challenges and contradictions10.1016/j.molonc.2014.02.009 ↗
34. Pecqueux, M., Liebetrau, I., Werft, W., Dienemann, H., Muley, T., Pfannschmidt, J., Mussle, B., Rahbari, N., Scholch, S., and Buchler, M.W. (2016). A comprehensive microRNA expression profile of liver and lung metastases of colorectal cancer with their corresponding host tissue and its prognostic impact on survival. Int. J. Mol. Sci., 17.10.3390/ijms17101755 ↗
35. Blood cell origin of circulating microRNAs: A cautionary note for cancer biomarker studies10.1158/1940-6207.CAPR-11-0370 ↗
36. Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations10.1073/pnas.1214046110 ↗
37. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: A retrospective multicenter cohort study10.1097/SLA.0000000000002660 ↗
38. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas10.1182/blood-2008-10-184077 ↗
39. MicroRNA miR-125b causes leukemia10.1073/pnas.1016611107 ↗
40. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets10.1073/pnas.1016218107 ↗
41. Immunoglobulin G4 (IgG4)-positive plasma cell infiltration is associated with the clinicopathologic traits and prognosis of pancreatic cancer after curative resection10.1007/s00262-016-1853-2 ↗
42. Huang, X., Yuan, T., Tschannen, M., Sun, Z., Jacob, H., Du, M., Liang, M., Dittmar, R.L., Liu, Y., and Liang, M. (2013). Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genom., 14.10.1186/1471-2164-14-319 ↗
43. MicroRNA-Containing T-Regulatory-Cell-Derived Exosomes Suppress Pathogenic T Helper 1 Cells10.1016/j.immuni.2014.05.019 ↗
44. Mapping circulating serum miRNAs to their immune-related target mRNAs
45. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells10.1038/ncomms1285 ↗
46. MiR-125b-5p and miR-99a-5p downregulate human gammadelta T-cell activation and cytotoxicity10.1038/cmi.2017.164 ↗
47. MiR-10a-5p, miR-99a-5p and miR-21-5p are steroid-responsive circulating microRNAs
48. MiR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells10.2147/OTT.S114276 ↗
49. Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients10.3748/wjg.v24.i11.1206 ↗
50. MTOR signaling in T cell immunity and autoimmunity10.3109/08830185.2014.933957 ↗
51. The role of mTOR-mediated signals during haemopoiesis and lineage commitment10.1042/BST20180141 ↗
52. Critical roles of mTORC1 signaling and metabolic reprogramming for M-CSF-mediated myelopoiesis10.1084/jem.20161855 ↗
53. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis10.1073/pnas.1412608111 ↗
54. Liver-specific microRNA-122: Biogenesis and function10.4161/rna.18827 ↗
55. Distribution of miRNA expression across human tissues10.1093/nar/gkw116 ↗
56. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer10.1002/bjs.10870 ↗
57. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: A prospective, randomized, open-label, multicenter phase 2/3 trial10.1097/SLA.0000000000002705 ↗
58. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial10.1200/JCO.2018.36.18_suppl.LBA4002 ↗
59. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: A systematic review and patient-level meta-analysis10.1093/jnci/djz073 ↗
60. Chemotherapy and tumor microenvironment of pancreatic cancer10.1186/s12935-017-0437-3 ↗
61. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas10.1007/s00262-004-0638-1 ↗